Northeast Pharmaceutical Group Co., Ltd. (SHE:000597)
China · Delayed Price · Currency is CNY 5.20
+0.05 (0.97%)
Feb 3, 2026, 3:04 PM CST
SHE:000597 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 6,793 | 7,448 | 8,185 | 8,719 | 8,046 | 7,300 |
Other Revenue | 54.09 | 54.09 | 58.56 | 89.5 | 98.7 | 84.31 |
| 6,847 | 7,503 | 8,243 | 8,809 | 8,145 | 7,384 | |
Revenue Growth (YoY) | -14.12% | -8.98% | -6.42% | 8.15% | 10.30% | -10.17% |
Cost of Revenue | 4,285 | 4,741 | 5,125 | 5,557 | 5,056 | 4,596 |
Gross Profit | 2,562 | 2,761 | 3,118 | 3,252 | 3,089 | 2,789 |
Selling, General & Admin | 1,899 | 2,096 | 2,579 | 2,767 | 2,698 | 2,452 |
Research & Development | 168.3 | 117.76 | 97.04 | 160.39 | 83.46 | 74.18 |
Other Operating Expenses | 72.2 | 77.34 | 81.75 | 83.13 | 83.86 | 48.04 |
Operating Expenses | 2,133 | 2,285 | 2,752 | 3,032 | 2,879 | 2,575 |
Operating Income | 429.78 | 475.95 | 366.2 | 219.56 | 210.63 | 213.53 |
Interest Expense | -47.24 | -64.53 | -78.36 | -92.11 | -120.16 | -120.87 |
Interest & Investment Income | 101.34 | 133.79 | 163.69 | 93.88 | 110.25 | 58.43 |
Currency Exchange Gain (Loss) | 10.06 | 10.06 | 8.11 | 28.68 | -6.45 | -18.02 |
Other Non Operating Income (Expenses) | -56.95 | -49.15 | -54.94 | -37.85 | -47.68 | -22.04 |
EBT Excluding Unusual Items | 436.98 | 506.12 | 404.7 | 212.15 | 146.59 | 111.04 |
Gain (Loss) on Sale of Assets | 6.93 | 6.19 | 0.17 | 419.3 | 3.29 | 12.29 |
Asset Writedown | -19.95 | -10.12 | -3.9 | -7.97 | -28.96 | -23.17 |
Other Unusual Items | 60.36 | 91.72 | 87.21 | -98.04 | -0.76 | -8.32 |
Pretax Income | 484.7 | 593.91 | 488.17 | 525.44 | 120.16 | 91.84 |
Income Tax Expense | 120.43 | 170.63 | 112.19 | 168.28 | 24.72 | 81.01 |
Earnings From Continuing Operations | 364.27 | 423.28 | 375.98 | 357.16 | 95.44 | 10.83 |
Minority Interest in Earnings | 10.31 | -13.43 | -17.52 | -6.9 | 3.59 | 1.43 |
Net Income | 374.58 | 409.85 | 358.46 | 350.25 | 99.03 | 12.26 |
Net Income to Common | 374.58 | 409.85 | 358.46 | 350.25 | 99.03 | 12.26 |
Net Income Growth | 8.06% | 14.34% | 2.34% | 253.69% | 707.93% | -92.95% |
Shares Outstanding (Basic) | 1,413 | 1,413 | 1,434 | 1,401 | 1,415 | 1,226 |
Shares Outstanding (Diluted) | 1,413 | 1,413 | 1,434 | 1,401 | 1,415 | 1,226 |
Shares Change (YoY) | -1.21% | -1.43% | 2.34% | -0.97% | 15.42% | -8.41% |
EPS (Basic) | 0.27 | 0.29 | 0.25 | 0.25 | 0.07 | 0.01 |
EPS (Diluted) | 0.27 | 0.29 | 0.25 | 0.25 | 0.07 | 0.01 |
EPS Growth | 9.38% | 16.00% | - | 257.14% | 600.00% | -92.31% |
Free Cash Flow | 624.48 | 599.34 | 351.32 | 864.44 | 626.7 | 170.54 |
Free Cash Flow Per Share | 0.44 | 0.42 | 0.24 | 0.62 | 0.44 | 0.14 |
Dividend Per Share | 0.100 | 0.100 | 0.100 | 0.100 | 0.014 | 0.008 |
Dividend Growth | - | - | - | 614.29% | 75.00% | - |
Gross Margin | 37.42% | 36.81% | 37.83% | 36.92% | 37.93% | 37.76% |
Operating Margin | 6.28% | 6.34% | 4.44% | 2.49% | 2.59% | 2.89% |
Profit Margin | 5.47% | 5.46% | 4.35% | 3.98% | 1.22% | 0.17% |
Free Cash Flow Margin | 9.12% | 7.99% | 4.26% | 9.81% | 7.69% | 2.31% |
EBITDA | 970.63 | 1,019 | 911.39 | 754.38 | 722.45 | 694.29 |
EBITDA Margin | 14.18% | 13.58% | 11.06% | 8.56% | 8.87% | 9.40% |
D&A For EBITDA | 540.85 | 542.71 | 545.19 | 534.82 | 511.82 | 480.76 |
EBIT | 429.78 | 475.95 | 366.2 | 219.56 | 210.63 | 213.53 |
EBIT Margin | 6.28% | 6.34% | 4.44% | 2.49% | 2.59% | 2.89% |
Effective Tax Rate | 24.85% | 28.73% | 22.98% | 32.03% | 20.57% | 88.21% |
Revenue as Reported | 6,847 | 7,503 | 8,243 | 8,809 | 8,145 | 7,384 |
Advertising Expenses | - | - | - | 7.13 | 10.53 | 3.35 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.